In hepatocellular carcinoma (HCC), sorafenib (Sora) efficacy is limited by primary and/or
acquired resistance. Emerging evidence shows that the inflammatory factor interleukin 6 (IL …

Sorafenib is the only chemotherapeutic agent currently approved for unresectable
hepatocellular carcinoma (HCC). However, poor response rates have been widely reported …

Sorafenib is a targeted drug for hepatocellular carcinoma (HCC), however, its efficacy is
limited. Nuclear factor erythroid 2‑related factor 2 (Nrf2) contributes to sorafenib resistance …

Simple Summary Sorafenib resistance is the major challenge for the unsatisfactory response
to targeted therapies in advanced hepatocellular carcinoma (HCC). Combination therapy …

Norcantharidin (NCTD) is a water-soluble synthetic small molecule drug that has been
approved by the Chinese FDA for the treatment of cancer in China. Among these NCTD …

Sorafenib has been approved for the treatment of advanced stage hepatocellular carcinoma
but has limited efficacy. Ursodeoxycholic acid exerts cytoprotective activities in hepatocytes …

Sorafenib (SOR) is the first-line treatment for hepatocellular carcinoma (HCC). However, its
use is hindered by the recently expressed safety concerns. One approach for reducing SOR …

SL1122-37 is a novel derivative of sorafenib that was characterized by introducing
trifluoromethyl on the 4-position of indazole. We aimed to evaluate the effects of SL1122-37 …

Sorafenib, a multikinase inhibitor, is the first-line agent for advanced liver cancer. Sorafenib
strongly inhibits both cell proliferation and tumour angiogenesis. However, the development …

Hepatocellular carcinoma (HCC) ranks as the third leading cause of cancer-related mortality
worldwide. The global burden of HCC is increasing with an annual incidence of 1 million …